Earnings ·
GeoVax Labs reported a net loss of $4.4 million ($0.97 per share) for the second quarter of 2026, compared to a net…
GOVXWGeoVax Labs, Inc.
GeoVax Labs reported a net loss of $4.4 million ($0.97 per share) for the second quarter of 2026, compared to a net loss of $5.4 million for the same period in 2025. The company reported zero revenue for the quarter, following the termination of its BARDA contract for the GEO-CM04S1 COVID-19 vaccine program. GeoVax is now prioritizing its GEO-MVA vaccine for mpox and smallpox, with a pivotal immunobridging study planned for the fourth quarter of 2026, and its Gedeptin immuno-oncology program. As of June 30, 2026, the company held $3.1 million in cash. GeoVax is a clinical-stage biotechnology company developing vaccines and immunotherapies against infectious diseases and solid tumors.